Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Absenger, G; Szkandera, J; Pichler, M; Stotz, M; Arminger, F; Weissmueller, M; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A.
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.
Br J Cancer. 2013; 109(2):395-400
Doi: 10.1038/bjc.2013.346
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Absenger Gudrun
- Gerger Armin
- Co-Autor*innen der Med Uni Graz
- Pichler Martin
- Samonigg Hellmut
- Schaberl-Moser Renate
- Stojakovic Tatjana
- Stotz Michael
- Szkandera Joanna
- Weissmüller Melanie
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Inflammation has a critical role in the pathogenesis and progression of cancer. Recently, the derived neutrophil to lymphocyte ratio (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been shown to influence clinical outcome in various cancer entities. In this study, we analysed the dNLR with clinical outcome in stage II and III colon cancer patients. Methods: Three-hundred and seventy-two patients with stage II and III colon cancer were included in this retrospective study. Kaplan-Meier curves and multivariate Cox proportion analyses were calculated for time to recurrence (TTR) and overall survival (OS). Results: In univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (hazard ratio (HR) 2.38, 95% confidence interval (CI) 1.57-3.6, P<0.001) and remained significant in multivariate analysis. Patients with dNLR >3 had a median TTR of 83 months, and patients with dNLR <= 3 showed a median TTR of 132 months. In OS analysis, a dNLR >2.2 was significantly associated with decreased OS in univariate (HR 1.85, 95% CI 1.11-3.08, P = 0.018) and multivariate analysis. Patients with dNLR >2.2 showed a median OS of 121 months, and patients with dNLR <= 2.2 had a median OS of 147 months. Conclusion: The dNLR may be an independent prognostic marker for TTR and OS in patients with stage II and III colon cancer. Independent validation of our findings is warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Colonic Neoplasms - mortality Colonic Neoplasms - pathology
- Female -
- Humans -
- Leukocyte Count -
- Lymphocytes - pathology
- Male -
- Middle Aged -
- Neoplasm Staging -
- Neutrophils - pathology
- Prognosis -
- Retrospective Studies -
- Survival Analysis -
- Find related publications in this database (Keywords)
- colon cancer
- inflammation
- biomarker
- prognosis